Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada. Show more
2265 Upper Middle Road East, Oakville, ON, L6H 0G5, Canada
Start AI Chat
Market Cap
110.1M
52 Wk Range
$0.77 - $1.59
Previous Close
$0.99
Open
$1.00
Volume
274,894
Day Range
$0.99 - $1.03
Enterprise Value
74.14M
Cash
11.62M
Avg Qtr Burn
-6.925M
Insider Ownership
3.14%
Institutional Own.
20.04%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
CardiolRx™ Details Recurrent pericarditis | Phase 3 Data readout | |
CardiolRx™ Details Acute Myocarditis | Phase 2 Update | |
CardiolRx™ Details COVID-19 | Failed Discontinued |
